Q&A Project Optimus: What you need to know
The study designs and dose-finding strategies that have dominated decades of oncology drug development are becoming obsolete as the FDA’s Project Optimus takes full effect. We rounded up our regulatory experts and asked them to share their perspectives on 28 of the top questions from sponsors.
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Blog
Optimize your CMC strategy: Five steps to avoid regulatory setbacks
May 15, 2025
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Related Insights
Blog
Navigating the path to conditional approval: avoiding pitfalls in oncology drug applications
Feb 4, 2025
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Webinar
Advancing mRNA-based drug development and vaccine manufacturing
Jul 1, 2024
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Blog
Optimize your CMC strategy: Five steps to avoid regulatory setbacks
May 15, 2025
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023